159 related articles for article (PubMed ID: 37303494)
41. Downregulation of miR-34a contributes to the proliferation and migration of laryngeal carcinoma cells by targeting cyclin D1.
Ye J; Li L; Feng P; Wan J; Li J
Oncol Rep; 2016 Jul; 36(1):390-8. PubMed ID: 27220728
[TBL] [Abstract][Full Text] [Related]
42. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC.
Christoffersen NR; Shalgi R; Frankel LB; Leucci E; Lees M; Klausen M; Pilpel Y; Nielsen FC; Oren M; Lund AH
Cell Death Differ; 2010 Feb; 17(2):236-45. PubMed ID: 19696787
[TBL] [Abstract][Full Text] [Related]
43. Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy.
Dalmasso B; Hatse S; Brouwers B; Laenen A; Berben L; Kenis C; Smeets A; Neven P; Schöffski P; Wildiers H
BMC Cancer; 2018 Oct; 18(1):1014. PubMed ID: 30348127
[TBL] [Abstract][Full Text] [Related]
44. Pilot Study of Serum MicroRNA-21 as a Diagnostic and Prognostic Biomarker in Egyptian Breast Cancer Patients.
Toraih EA; Mohammed EA; Farrag S; Ramsis N; Hosny S
Mol Diagn Ther; 2015 Jun; 19(3):179-90. PubMed ID: 26063582
[TBL] [Abstract][Full Text] [Related]
45. MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1.
Zhou Y; Ding BZ; Lin YP; Wang HB
Gene; 2018 Feb; 644():56-65. PubMed ID: 29054762
[TBL] [Abstract][Full Text] [Related]
46. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
47. Layer-by-layer assembled PLGA nanoparticles carrying miR-34a cargo inhibit the proliferation and cell cycle progression of triple-negative breast cancer cells.
Kapadia CH; Ioele SA; Day ES
J Biomed Mater Res A; 2020 Mar; 108(3):601-613. PubMed ID: 31742868
[TBL] [Abstract][Full Text] [Related]
48. Transcriptome-wide characterization of the endogenous miR-34A-p53 tumor suppressor network.
Samuel N; Wilson G; Id Said B; Pan A; Deblois G; Fischer NW; Alexandrova R; Casallo G; Paton T; Lupien M; Gariepy J; Merico D; Hudson TJ; Malkin D
Oncotarget; 2016 Aug; 7(31):49611-49622. PubMed ID: 27391063
[TBL] [Abstract][Full Text] [Related]
49. MicroRNAs as biomarkers of cervical cancer development: a literature review on miR-125b and miR-34a.
Ribeiro J; Sousa H
Mol Biol Rep; 2014 Mar; 41(3):1525-31. PubMed ID: 24402874
[TBL] [Abstract][Full Text] [Related]
50. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene.
Cole KA; Attiyeh EF; Mosse YP; Laquaglia MJ; Diskin SJ; Brodeur GM; Maris JM
Mol Cancer Res; 2008 May; 6(5):735-42. PubMed ID: 18505919
[TBL] [Abstract][Full Text] [Related]
51. Apoptotic effects of valproic acid on miR-34a, miR-520h and HDAC1 gene in breast cancer.
Injinari N; Amini-Farsani Z; Yadollahi-Farsani M; Teimori H
Life Sci; 2021 Mar; 269():119027. PubMed ID: 33453248
[TBL] [Abstract][Full Text] [Related]
52. Dual role for miR-34a in the control of early progenitor proliferation and commitment in the mammary gland and in breast cancer.
Bonetti P; Climent M; Panebianco F; Tordonato C; Santoro A; Marzi MJ; Pelicci PG; Ventura A; Nicassio F
Oncogene; 2019 Jan; 38(3):360-374. PubMed ID: 30093634
[TBL] [Abstract][Full Text] [Related]
53. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis.
Kumar B; Yadav A; Lang J; Teknos TN; Kumar P
PLoS One; 2012; 7(5):e37601. PubMed ID: 22629428
[TBL] [Abstract][Full Text] [Related]
54. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
Ma Y; Qin H; Cui Y
Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
[TBL] [Abstract][Full Text] [Related]
55. Loss of post-transcriptional regulation of DNMT3b by microRNAs: a possible molecular mechanism for the hypermethylation defect observed in a subset of breast cancer cell lines.
Sandhu R; Rivenbark AG; Coleman WB
Int J Oncol; 2012 Aug; 41(2):721-32. PubMed ID: 22664488
[TBL] [Abstract][Full Text] [Related]
56. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
[TBL] [Abstract][Full Text] [Related]
57. MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1.
Li XJ; Ji MH; Zhong SL; Zha QB; Xu JJ; Zhao JH; Tang JH
Arch Med Res; 2012 Oct; 43(7):514-21. PubMed ID: 23085450
[TBL] [Abstract][Full Text] [Related]
58. Dysregulation of microRNA-34a expression in colorectal cancer inhibits the phosphorylation of FAK via VEGF.
Zhang D; Zhou J; Dong M
Dig Dis Sci; 2014 May; 59(5):958-67. PubMed ID: 24370784
[TBL] [Abstract][Full Text] [Related]
59. MitomiRs in human inflamm-aging: a hypothesis involving miR-181a, miR-34a and miR-146a.
Rippo MR; Olivieri F; Monsurrò V; Prattichizzo F; Albertini MC; Procopio AD
Exp Gerontol; 2014 Aug; 56():154-63. PubMed ID: 24607549
[TBL] [Abstract][Full Text] [Related]
60. Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion.
Li L; Xie X; Luo J; Liu M; Xi S; Guo J; Kong Y; Wu M; Gao J; Xie Z; Tang J; Wang X; Wei W; Yang M; Hung MC; Xie X
Mol Ther; 2012 Dec; 20(12):2326-34. PubMed ID: 23032974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
